RAPTOR PHARMACEUTICAL CORP

Inactive Instrument

Raptor Pharmaceutical Corp Share Price

Equities

US75382F1066

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2016

Exclusive: Drugmaker Depomed prepares to explore a sale - sources

RE

Latest news about Raptor Pharmaceutical Corp

Exclusive: Drugmaker Depomed prepares to explore a sale - sources

15/09/16

RE

Press releases Raptor Pharmaceutical Corp

Brower Piven Commences An Investigation Into The Proposed Sale Of Raptor Pharmaceutical Corp. And Encourages Shareholders To Contact The Firm For Additional Information	15/09/16	BU
Raptor Pharmaceutical : Acquisition May Not Be in the Best Interests of RPTP Shareholders	13/09/16	PR
Brower Piven Commences An Investigation Into The Proposed Sale Of Raptor Pharmaceutical Corp. And Encourages Investors To Contact The Firm For Additional Information	12/09/16	BU
RAPTOR PHARMACEUTICAL CORP. Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Horizon Pharma plc	12/09/16	BU
Raptor Pharmaceutical Presents Results from Meta-Analysis Demonstrating Efficacy of QUINSAIR™ Comparable to Other Approved, Inhaled Antibiotics in Cystic Fibrosis Patients	07/09/16	GL

More press releases

News in other languages on Raptor Pharmaceutical Corp

Depomed : Le laboratoire Depomed résigné à se vendre-sources	15/09/16
Apple : Les valeurs à suivre sur les marchés aùéricains	14/09/15
Raptor Pharmaceutical Corp. : Raptor Pharmaceutical termine le recrutement de la phase 2/3 de l’essai clinique du RP103 pour le traitement potentiel de la maladie de Huntington	19/06/12
Raptor Pharmaceutical Corp. : Raptor Pharmaceutical annonce la publication des résultats de phase III dans le Clinical Journal of the American Society of Nephrology	07/05/12
Rapr Phar : Raptor Pharmaceutical tiendra, le mardi 26 juillet 2011 à midi heure de l’Est des États-Unis, une conférence téléphonique et une webdiffusion pour discuter des résultats des essais cliniques de Phase 3	27/07/11

Managers and Directors - Raptor Pharmaceutical Corp

Managers	Title	Age	Since
Paul Hoelscher DFI	Director of Finance/CFO	59	24/10/16
Kim Lee IRC	Investor Relations Contact	-	22/10/14
Françoise de Craecker PRN	Corporate Officer/Principal	62	-

Members of the board	Title	Age	Since
Gregg Lapointe CHM	Chairman	65	31/12/14
Timothy Walbert BRD	Director/Board Member	57	10/04/11
Paul Hoelscher DFI	Director of Finance/CFO	59	24/10/16

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	113B
REGENERON PHARMACEUTICALS, INC.	+10.21%	106B
ARGENX SE	+0.41%	22.27B
BIONTECH SE	-11.90%	22.22B
GENMAB A/S	-5.99%	19.43B
WUXI APPTEC CO., LTD.	-37.36%	17.87B
BEIGENE, LTD.	-5.17%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.29B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.52B

Bio Therapeutic Drugs

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer